地塞米松治疗急性呼吸窘迫综合征

Q4 Medicine

Clinical Pulmonary Medicine Pub Date : 2020-09-01 DOI:10.1097/cpm.0000000000000378

W. Whalen, D. Zappetti

{"title":"地塞米松治疗急性呼吸窘迫综合征","authors":"W. Whalen, D. Zappetti","doi":"10.1097/cpm.0000000000000378","DOIUrl":null,"url":null,"abstract":"Synopsis: In patients with moderate-to-severe acute respiratory distress syndrome (ARDS), defined as an arterial oxygen partial pressure/ fractional inspired oxygen (PaO2/FiO2) of 200 mmHg or less with a positive end-expiratory pressure (PEEP) of 10 cm H2O or greater and FiO2 > 0.5, administration of dexamethasone within 24 hours of ARDS onset led to more ventilator-free days, and a reduction of all-cause mortality with no difference in adverse events. Source: Villar, J, Ferrando, C, Martínez, D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicenter, randomised controlled trial. Lancet Respir Med. 2020;8:267–276.","PeriodicalId":10393,"journal":{"name":"Clinical Pulmonary Medicine","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dexamethasone in Acute Respiratory Distress Syndrome\",\"authors\":\"W. Whalen, D. Zappetti\",\"doi\":\"10.1097/cpm.0000000000000378\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Synopsis: In patients with moderate-to-severe acute respiratory distress syndrome (ARDS), defined as an arterial oxygen partial pressure/ fractional inspired oxygen (PaO2/FiO2) of 200 mmHg or less with a positive end-expiratory pressure (PEEP) of 10 cm H2O or greater and FiO2 > 0.5, administration of dexamethasone within 24 hours of ARDS onset led to more ventilator-free days, and a reduction of all-cause mortality with no difference in adverse events. Source: Villar, J, Ferrando, C, Martínez, D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicenter, randomised controlled trial. Lancet Respir Med. 2020;8:267–276.\",\"PeriodicalId\":10393,\"journal\":{\"name\":\"Clinical Pulmonary Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Pulmonary Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/cpm.0000000000000378\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pulmonary Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/cpm.0000000000000378","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

简介：在中重度急性呼吸窘迫综合征（ARDS）患者中，定义为动脉氧分压/吸入氧分压（PaO2/FiO2）为200mmHg或更低，呼气末正压（PEEP）为10cm H2O或更大，FiO2>0.5，在ARDS发作后24小时内给予地塞米松可导致更多的无呼吸机天数，以及在不良事件没有差异的情况下降低全因死亡率。资料来源：Villar，J，Ferrando，C，Martínez，D等。地塞米松治疗急性呼吸窘迫综合征：一项多中心随机对照试验。《柳叶刀呼吸医学》2020；8:267–276。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Dexamethasone in Acute Respiratory Distress Syndrome

Synopsis: In patients with moderate-to-severe acute respiratory distress syndrome (ARDS), defined as an arterial oxygen partial pressure/ fractional inspired oxygen (PaO2/FiO2) of 200 mmHg or less with a positive end-expiratory pressure (PEEP) of 10 cm H2O or greater and FiO2 > 0.5, administration of dexamethasone within 24 hours of ARDS onset led to more ventilator-free days, and a reduction of all-cause mortality with no difference in adverse events. Source: Villar, J, Ferrando, C, Martínez, D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicenter, randomised controlled trial. Lancet Respir Med. 2020;8:267–276.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Pulmonary Medicine Medicine-Critical Care and Intensive Care Medicine

自引率

0.00%

发文量

期刊介绍： Clinical Pulmonary Medicine provides a forum for the discussion of important new knowledge in the field of pulmonary medicine that is of interest and relevance to the practitioner. This goal is achieved through mini-reviews on focused sub-specialty topics in areas covered within the journal. These areas include: Obstructive Airways Disease; Respiratory Infections; Interstitial, Inflammatory, and Occupational Diseases; Clinical Practice Management; Critical Care/Respiratory Care; Colleagues in Respiratory Medicine; and Topics in Respiratory Medicine.